A genetically engineered, stem-cell-derived cellular vaccine.
Date
2022-12
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
Despite rapid clinical translation of COVID-19 vaccines in response to the global pandemic, an opportunity remains for vaccine technology innovation to address current limitations and meet challenges of inevitable future pandemics. We describe a universal vaccine cell (UVC) genetically engineered to mimic natural physiological immunity induced upon viral infection of host cells. Cells engineered to express the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike as a representative viral antigen induce robust neutralizing antibodies in immunized non-human primates. Similar titers generated in this established non-human primate (NHP) model have translated into protective human neutralizing antibody levels in SARS-CoV-2-vaccinated individuals. Animals vaccinated with ancestral spike antigens and subsequently challenged with SARS-CoV-2 Delta variant in a heterologous challenge have an approximately 3 log decrease in viral subgenomic RNA in the lungs. This cellular vaccine is designed as a scalable cell line with a modular poly-antigenic payload, allowing for rapid, large-scale clinical manufacturing and use in an evolving viral variant environment.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Cooper, Amanda, Adam Sidaway, Abishek Chandrashekar, Elizabeth Latta, Krishnendu Chakraborty, Jingyou Yu, Katherine McMahan, Victoria Giffin, et al. (2022). A genetically engineered, stem-cell-derived cellular vaccine. Cell reports. Medicine, 3(12). p. 100843. 10.1016/j.xcrm.2022.100843 Retrieved from https://hdl.handle.net/10161/26543.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Cordelia Manickam
Roger Keith Reeves
Dr. Reeves obtained his Ph.D. at the University of Alabama-Birmingham studying dendritic cell biology in lentivirus infections, then completed his postdoctoral training in lentivirus vaccinology, natural killer cells, and innate immunity at the New England Primate Research Center, Massachusetts General Hospital, and Harvard Medical School (HMS). He later became faculty at HMS and Beth Israel Deaconess Medical Center through the rank of Associate Professor. Upon being recruited to Duke University in 2021, Dr. Reeves became a tenured Professor in the Department of Surgery and the Department of Pathology and Director in the Duke Center for Human Systems Immunology. He currently serves as Editor-in-Chief of the journal AIDS Research and Human Retroviruses and is the immediate past chair of the NIH HIV Immunopathogenesis and Vaccine Development study section. Dr. Reeves also previously sat on NIH F13 fellowship study sections, has served on the HVTN ESI Advisory board for over a decade, and currently is Director of the Duke Center for AIDS Research Developmental Core, collectively mentoring dozens of trainees at all levels. Dr. Reeves’ research has been continuously supported by NIH for well over 15 years, having served as PI on multiple R and P grants in addition to participating in consortia grants such as the HIV Vaccine Trials Network and BEAT-HIV Delaney Cure Collaboratory. Considered a global expert in natural killer cell biology, his research has provided some of the most detailed characterizations of NK cell responses against viruses, and his team was the first to identify memory and memory-like NK cells in humans and nonhuman primates. With over 100 publications in the field and over 60 as senior author, Dr. Reeves’ group continues to focus on cutting-edge approaches to harness NK cells in the context of vaccines and immunotherapeutics for HIV, CMV, HCV, influenza, SARS-CoV-2, congenital CMV, and cancer.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.